Glioblastoma stem cells therapy
胶质母细胞瘤干细胞治疗
基本信息
- 批准号:8308009
- 负责人:
- 金额:$ 37.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAnimal ModelAntineoplastic AgentsApoptosisAreaAstrocytesBiological AssayBiological FactorsBloodBlood - brain barrier anatomyBostonBrainBrain NeoplasmsCaringCell ProliferationCell SurvivalCellsCentral Nervous System NeoplasmsComplexDisease ProgressionDoseEngineered GeneEvaluationExcisionFibroblastsFluorescenceGene TransferGlioblastomaGliomaHospitalsIn VitroInduction of ApoptosisInhibitory Concentration 50LaboratoriesLibrariesLigandsLuciferasesMalignant - descriptorMeasurementMetabolicModelingMolecularNeoplasm MetastasisNerve DegenerationNeuronsNude MiceOperative Surgical ProceduresPatientsPenetrationPharmaceutical ChemistryPharmaceutical PreparationsPhenocopyPreclinical Drug EvaluationPreclinical TestingPropertyRadiationRecurrenceReporterResearchResectedResistanceScreening procedureSpecificityStem cellsStromal CellsSurvival RateTestingTherapeuticTimeToxic effectTreatment EfficacyTumor Necrosis Factor-alphaUnited States Food and Drug AdministrationValidationWomanWorkXenograft procedureabstractingadeno-associated viral vectoranalogbasecancer cellcancer stem cellchemotherapyconventional therapydrug candidatedrug discoveryhigh throughput screeningin vivoin vivo Modelkillingsneoplastic cellnovelpreventrelating to nervous systemresearch studysmall moleculesmall molecule librariesstemstem cell therapysubcutaneoustumortumor registrytumor xenograft
项目摘要
Abstract
Gliomas account for about 60% of all primary CNS tumors. Glioblastoma (GBM) or grade IV gliomas which
comprise 50.9% of all gliomas are the most malignant form. Glioblastoma tumors are highly heterogeneous
and there is a complex interaction among different types of tumor cells and stromal cells within the tumor.
Recently it has been shown that the majority of tumor cells do not have the capacity to recapitulate a
phenocopy of the original tumor and that only a small subpopulation of cells in the tumor, called cancer stem
cells, have that ability upon xenotransplantation in nude mice. These cancer stem cells appear to be more
resistant to conventional therapy, like chemotherapy and radiation, as compared to the non-cancer stem cells.
Following current therapy for high-grade glioma tumors, most patients die within a year from a new secondary
tumor foci forming within one centimeter of the resected area. These foci are enriched for cancer stem cells,
and it is likely that they are responsible for tumor recurrence. Our proposal focuses on identifying small
molecule drugs which can increase therapeutic efficacy for GBM stem cells. Tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is regarded as a potential anti-cancer agent. However, a considerable
number of different types of cancer cells, including GBM, are resistant to apoptosis induction by TRAIL. We
plan to identity drug candidates which either kill primary GBM stem cells directly or can sensitize these cells to
TRAIL-induced apoptosis. We will use a high throughput apoptosis-screening assay which we have developed
based on the naturally secreted Gaussia luciferase and screen different small molecule libraries including ones
containing FDA-approved drugs which crosses the blood-brain barrier. We will validate the most promising
drug hits in our experimental glioma stem cells-bioluminescent model in vivo.
摘要
神经胶质瘤占所有原发性CNS肿瘤的约60%。胶质母细胞瘤(GBM)或IV级胶质瘤,
占所有胶质瘤的50.9%,是最恶性的形式。胶质母细胞瘤肿瘤是高度异质性的
并且在肿瘤内不同类型的肿瘤细胞和基质细胞之间存在复杂的相互作用。
最近研究表明,大多数肿瘤细胞没有重演肿瘤细胞凋亡的能力。
表型复制的原始肿瘤,只有一个小的细胞亚群在肿瘤中,称为癌症干细胞
细胞在裸鼠中异种移植时具有这种能力。这些癌症干细胞似乎比
与非癌症干细胞相比,它们对常规疗法如化疗和放疗具有抗性。
在目前治疗高级别胶质瘤后,大多数患者在一年内死于新的继发性胶质瘤。
肿瘤病灶在切除区域的一厘米内形成。这些病灶富含癌症干细胞,
并且它们很可能是肿瘤复发的原因。我们的建议侧重于确定小
分子药物,可以增加GBM干细胞的治疗效果。肿瘤坏死因子相关
肿瘤坏死诱导配体(TRAIL)被认为是一种潜在的抗癌药物。然而,相当多的
许多不同类型的癌细胞,包括GBM,对TRAIL诱导的凋亡具有抗性。我们
他们计划鉴定候选药物,这些药物可以直接杀死原代GBM干细胞,也可以使这些细胞敏感,
TRAIL诱导的细胞凋亡。我们将使用我们开发的高通量细胞凋亡筛选试验
基于天然分泌的Gaussia荧光素酶,筛选不同的小分子文库,
含有FDA批准的能穿过血脑屏障的药物我们将验证最有希望的
在我们的实验性胶质瘤干细胞体内生物发光模型中的药物命中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BAKHOS A TANNOUS其他文献
BAKHOS A TANNOUS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BAKHOS A TANNOUS', 18)}}的其他基金
Radiation-induced targeted extracellular vesicles -based gene delivery for glioma therapy
放射诱导的基于细胞外囊泡的基因递送用于神经胶质瘤治疗
- 批准号:
9902892 - 财政年份:2019
- 资助金额:
$ 37.94万 - 项目类别:
Radiation-induced targeted extracellular vesicles -based gene delivery for glioma therapy
放射诱导的基于细胞外囊泡的基因递送用于神经胶质瘤治疗
- 批准号:
10058293 - 财政年份:2019
- 资助金额:
$ 37.94万 - 项目类别:
Screening for adjuvant gliobalstoma therapeutics
胶质母细胞瘤辅助治疗的筛选
- 批准号:
9127592 - 财政年份:2016
- 资助金额:
$ 37.94万 - 项目类别:
Screening for adjuvant gliobalstoma therapeutics
胶质母细胞瘤辅助治疗的筛选
- 批准号:
9244081 - 财政年份:2016
- 资助金额:
$ 37.94万 - 项目类别:
Blood-based assays for the detection of glioblastoma RNA biomarkers
用于检测胶质母细胞瘤 RNA 生物标志物的血液检测
- 批准号:
9149048 - 财政年份:2015
- 资助金额:
$ 37.94万 - 项目类别:
Detection of NSCLC-derived mutant RNA in platelets
血小板中 NSCLC 衍生突变 RNA 的检测
- 批准号:
8589148 - 财政年份:2013
- 资助金额:
$ 37.94万 - 项目类别:
Detection of NSCLC-derived mutant RNA in platelets
血小板中 NSCLC 衍生突变 RNA 的检测
- 批准号:
8692700 - 财政年份:2013
- 资助金额:
$ 37.94万 - 项目类别:
Screening for modulators of glioma stem cells differentiation
神经胶质瘤干细胞分化调节剂的筛选
- 批准号:
8452232 - 财政年份:2013
- 资助金额:
$ 37.94万 - 项目类别:
Screening for modulators of glioma stem cells differentiation
神经胶质瘤干细胞分化调节剂的筛选
- 批准号:
8605810 - 财政年份:2013
- 资助金额:
$ 37.94万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 37.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists